Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 15/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | BCL2 | P10415 | 4/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408809 | 1.00 | P2RX3 (0.41) | P2RX3MCL1CCNT1CDK9BCL2 | |
| SCHEMBL27017367 | 0.89 | MCL1 (0.44) | P2RX3MCL1BCL2BCL2L1NR1H2 | |
| SCHEMBL2409780 | 0.85 | P2RX3 (0.43) | P2RX3MCL1CCNT1CDK9NR1H2 | |
| SCHEMBL2409775 | 0.85 | P2RX3 (0.43) | P2RX3MCL1CCNT1CDK9NR1H2 | |
| SCHEMBL24739225 | 0.84 | CCNT1 (0.44) | P2RX3CCNT1CDK9NR1H2NR1H3 | |
| SCHEMBL5152159 | 0.84 | CCNT1 (0.44) | P2RX3CCNT1CDK9NR1H2NR1H3 | |
| SCHEMBL12319154 | 0.83 | P2RX3 (0.41) | P2RX3MCL1CCNT1CDK9NR1H2 | |
| SCHEMBL30170377 | 0.81 | P2RX3 (0.41) | P2RX3MCL1BCL2BCL2L1NR1H2 | |
| SCHEMBL27017548 | 0.81 | P2RX3 (0.41) | P2RX3MCL1BCL2BCL2L1NR1H2 | |
| SCHEMBL13481242 | 0.80 | NR1H2 (0.43) | P2RX3MCL1CCNT1CDK9NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539346-B1 | 4-[HETEROCYCLOALKYLOXY(HETERO)ARYLAMINO] THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2014-04-16 | — | — | EP | disclosed |
| US-8648068-B2 | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212102-A1 | HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, TNK2, CMPK1 | P2RX3 852/4885MCL1 3278/4885CCNT1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.